

Abington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	13	13.6	95.8	(51.0-163.9)	Male	11	9.4	116.5	(58.1-208.5)
Female	7	5.6	125.2	(50.1-257.9)	Female	10	8.6	116.2	(55.7-213.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	3.0	nc	(nc-nc)	Male	6	3.0	198.9	(72.6-432.9)
Female	4	2.8	nc	(nc-nc)	Female	2	2.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.5	nc	(nc-nc)	Male	1	8.4	nc	(nc-nc)
Female	62	68.8	90.1	(69.1-115.5)	Female	4	8.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	2.4	nc	(nc-nc)	Male	5	7.6	65.6	(21.1-153.1)
<u>Colon / Rectum</u>					Female	6	3.6	167.0	(61.0-363.5)
Male	21	15.7	133.4	(82.6-203.9)	<u>Ovary</u>				
Female	22	16.6	132.3	(82.9-200.3)	Female	4	5.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	3.9	129.3	(41.7-301.7)	Male	8	5.1	155.9	(67.1-307.3)
Female	0	1.1	nc	(nc-nc)	Female	4	5.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.2	nc	(nc-nc)	Male	51	49.7	102.6	(76.4-134.9)
Female	3	1.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	3.5	nc	(nc-nc)
Male	17	8.7	195.2	(113.7-312.6)	Female	5	2.3	220.3	(71.0-514.2)
Female	7	5.3	131.6	(52.7-271.2)	<u>Testis</u>				
<u>Larynx</u>					Male	3	2.3	nc	(nc-nc)
Male	4	2.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	6	0.7	801.6	(292.7-1744.8)	Male	4	4.2	nc	(nc-nc)
<u>Leukemia</u>					Female	12	13.6	88.0	(45.4-153.7)
Male	3	5.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	7	4.9	143.0	(57.3-294.6)	Female	17	16.0	106.5	(62.0-170.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	6	5.5	109.2	(39.9-237.6)	Male	222	193.1	114.9	(100.3-131.1)
Female	2	2.0	nc	(nc-nc)	Female	245	225.3	108.7	(95.6-123.2)
<u>Lung and Bronchus</u>									
Male	39	25.1	155.4	(110.5-212.4)					
Female	38	29.6	128.2	(90.7-176.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Acton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	19	19.5	97.3	(58.6-152.0)	Male	15	13.8	108.7	(60.8-179.2)
Female	5	7.3	68.1	(22.0-159.0)	Female	16	11.3	141.5	(80.8-229.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	4.4	157.5	(63.1-324.6)	Male	4	4.4	nc	(nc-nc)
Female	2	3.7	nc	(nc-nc)	Female	5	3.5	142.0	(45.8-331.4)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.7	nc	(nc-nc)	Male	16	12.4	129.1	(73.7-209.6)
Female	114	94.7	120.3	(99.3-144.6)	Female	12	10.9	109.7	(56.6-191.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	3.3	nc	(nc-nc)	Male	13	11.3	114.6	(60.9-195.9)
<u>Colon / Rectum</u>					Female	5	4.8	104.7	(33.8-244.4)
Male	19	23.9	79.5	(47.8-124.1)	<u>Ovary</u>				
Female	22	22.9	95.9	(60.1-145.2)	Female	10	8.0	125.6	(60.1-231.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	7	5.5	126.8	(50.8-261.3)	Male	6	7.5	80.5	(29.4-175.1)
Female	4	1.4	nc	(nc-nc)	Female	7	7.5	93.2	(37.3-192.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.7	nc	(nc-nc)	Male	79	69.4	113.8	(90.1-141.8)
Female	1	1.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	5.1	nc	(nc-nc)
Male	4	12.8	nc	(nc-nc)	Female	2	3.1	nc	(nc-nc)
Female	9	7.2	125.8	(57.4-238.9)	<u>Testis</u>				
<u>Larynx</u>					Male	0	3.2	nc	(nc-nc)
Male	3	3.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	1.0	nc	(nc-nc)	Male	6	6.4	94.4	(34.5-205.5)
<u>Leukemia</u>					Female	17	18.1	93.8	(54.6-150.1)
Male	5	8.6	58.2	(18.7-135.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	10	6.3	159.1	(76.2-292.6)	Female	16	20.8	76.8	(43.9-124.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	8.1	nc	(nc-nc)	Male	236	279.3	84.5	(74.0-96.0)
Female	3	2.5	nc	(nc-nc)	Female	319	302.4	105.5	(94.2-117.7)
<u>Lung and Bronchus</u>									
Male	15	35.6	42.2	(23.6-69.6)					
Female	31	39.5	78.4	(53.3-111.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Acushnet

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	21	12.2	172.4	(106.7-263.6)	Male	6	7.7	78.1	(28.5-169.9)
Female	3	4.5	nc	(nc-nc)	Female	5	5.9	84.6	(27.3-197.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	2.3	nc	(nc-nc)	Male	2	2.5	nc	(nc-nc)
Female	0	1.9	nc	(nc-nc)	Female	4	2.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	9	6.9	130.3	(59.5-247.4)
Female	46	48.9	94.1	(68.9-125.5)	Female	8	6.2	128.3	(55.2-252.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.5	nc	(nc-nc)	Male	2	5.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	2.6	nc	(nc-nc)
Male	16	13.1	122.4	(69.9-198.9)	<u>Ovary</u>				
Female	13	13.1	99.3	(52.8-169.9)	Female	3	4.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	3.1	nc	(nc-nc)	Male	5	4.3	115.8	(37.3-270.2)
Female	0	0.9	nc	(nc-nc)	Female	5	4.6	108.2	(34.9-252.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	0.9	nc	(nc-nc)	Male	39	36.6	106.5	(75.7-145.6)
Female	0	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	2.9	nc	(nc-nc)
Male	7	6.7	105.2	(42.1-216.7)	Female	1	1.8	nc	(nc-nc)
Female	3	3.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.6	nc	(nc-nc)
Male	2	1.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.6	nc	(nc-nc)	Male	0	3.1	nc	(nc-nc)
<u>Leukemia</u>					Female	7	8.4	83.3	(33.4-171.7)
Male	3	4.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	8	3.5	228.3	(98.3-449.8)	Female	9	10.8	83.0	(37.9-157.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	4.1	nc	(nc-nc)	Male	173	154.7	111.8	(95.8-129.8)
Female	1	1.5	nc	(nc-nc)	Female	153	164.9	92.8	(78.7-108.7)
<u>Lung and Bronchus</u>									
Male	28	21.1	132.7	(88.2-191.8)					
Female	22	23.9	91.9	(57.6-139.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Adams

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	9.5	105.6	(50.6-194.2)	Male	3	5.9	nc	(nc-nc)
Female	3	3.9	nc	(nc-nc)	Female	5	5.1	98.3	(31.7-229.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.8	nc	(nc-nc)	Male	3	1.9	nc	(nc-nc)
Female	4	1.6	nc	(nc-nc)	Female	1	1.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	7	5.4	130.8	(52.4-269.5)
Female	34	41.9	81.2	(56.2-113.5)	Female	7	5.4	130.3	(52.2-268.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.3	nc	(nc-nc)	Male	5	4.5	111.5	(35.9-260.1)
<u>Colon / Rectum</u>					Female	0	2.2	nc	(nc-nc)
Male	9	10.2	88.2	(40.3-167.5)	<u>Ovary</u>				
Female	10	11.3	88.4	(42.3-162.6)	Female	3	3.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	2.4	nc	(nc-nc)	Male	3	3.4	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	4	3.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	0.7	nc	(nc-nc)	Male	30	30.3	98.9	(66.7-141.2)
Female	2	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	2.3	nc	(nc-nc)
Male	4	5.2	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
Female	4	3.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.2	nc	(nc-nc)
Male	0	1.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.5	nc	(nc-nc)	Male	3	2.3	nc	(nc-nc)
<u>Leukemia</u>					Female	7	7.2	97.6	(39.1-201.2)
Male	5	3.8	131.2	(42.3-306.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	3.0	nc	(nc-nc)	Female	7	9.3	75.4	(30.2-155.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	3.3	nc	(nc-nc)	Male	129	122.3	105.5	(88.1-125.3)
Female	0	1.3	nc	(nc-nc)	Female	130	142.0	91.6	(76.5-108.7)
<u>Lung and Bronchus</u>									
Male	24	16.8	143.2	(91.7-213.1)					
Female	25	20.9	119.9	(77.6-177.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Agawam

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	35	31.8	110.0	(76.6-152.9)	Male	21	20.4	103.1	(63.8-157.6)
Female	10	13.9	72.1	(34.5-132.6)	Female	15	17.7	84.5	(47.3-139.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	6.2	nc	(nc-nc)	Male	11	6.6	166.3	(82.9-297.6)
Female	5	5.6	90.0	(29.0-210.0)	Female	7	6.2	112.8	(45.2-232.5)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.1	nc	(nc-nc)	Male	24	18.3	131.3	(84.1-195.3)
Female	142	141.7	100.2	(84.4-118.1)	Female	17	18.8	90.3	(52.6-144.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	7	4.5	155.8	(62.4-321.0)	Male	23	15.5	148.0	(93.8-222.1)
<u>Colon / Rectum</u>					Female	13	7.8	166.1	(88.4-284.0)
Male	43	34.5	124.6	(90.1-167.8)	<u>Ovary</u>				
Female	34	40.6	83.8	(58.0-117.1)	Female	8	12.4	64.6	(27.8-127.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	8.4	nc	(nc-nc)	Male	10	11.5	86.9	(41.6-159.8)
Female	2	2.6	nc	(nc-nc)	Female	17	14.3	119.0	(69.3-190.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	2.3	nc	(nc-nc)	Male	88	104.3	84.4	(67.7-104.0)
Female	2	2.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	9	7.7	116.5	(53.2-221.1)
Male	27	18.1	149.1	(98.3-217.0)	Female	5	5.5	90.2	(29.1-210.6)
Female	6	11.4	52.6	(19.2-114.4)	<u>Testis</u>				
<u>Larynx</u>					Male	1	4.0	nc	(nc-nc)
Male	7	4.9	142.6	(57.1-293.7)	<u>Thyroid</u>				
Female	1	1.6	nc	(nc-nc)	Male	5	8.0	62.3	(20.1-145.4)
<u>Leukemia</u>					Female	18	24.3	74.0	(43.8-116.9)
Male	11	13.0	84.9	(42.3-151.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	9	10.8	83.0	(37.9-157.6)	Female	24	31.6	76.0	(48.7-113.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	13	11.4	113.7	(60.5-194.5)	Male	448	418.2	107.1	(97.4-117.5)
Female	5	4.4	113.1	(36.4-263.9)	Female	473	489.5	96.6	(88.1-105.7)
<u>Lung and Bronchus</u>									
Male	82	57.2	143.4	(114.0-178.0)					
Female	88	69.8	126.0	(101.1-155.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Alford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	1.0	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	3	3.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.2	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	<u>Ovary</u>				
Female	1	0.8	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	3.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	2	0.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.4	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.2	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.3	nc	(nc-nc)	Male	4	12.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	7	10.5	66.9	(26.8-137.9)
<u>Lung and Bronchus</u>									
Male	0	1.8	nc	(nc-nc)					
Female	0	1.6	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Amesbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	18	14.3	126.3	(74.8-199.6)	Male	8	10.3	77.9	(33.5-153.5)
Female	10	5.8	171.9	(82.3-316.2)	Female	5	8.8	56.7	(18.3-132.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	3.3	nc	(nc-nc)	Male	4	3.2	nc	(nc-nc)
Female	6	2.7	219.1	(80.0-476.8)	Female	0	2.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	12	9.1	131.4	(67.8-229.5)
Female	76	72.2	105.3	(83.0-131.8)	Female	10	8.6	117.0	(56.0-215.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.6	nc	(nc-nc)	Male	9	8.5	106.4	(48.5-201.9)
<u>Colon / Rectum</u>					Female	3	3.7	nc	(nc-nc)
Male	19	17.1	111.3	(67.0-173.8)	<u>Ovary</u>				
Female	20	17.7	113.1	(69.1-174.7)	Female	6	6.1	98.9	(36.1-215.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	4.1	nc	(nc-nc)	Male	8	5.5	145.2	(62.5-286.2)
Female	2	1.1	nc	(nc-nc)	Female	7	5.9	118.7	(47.5-244.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.4	nc	(nc-nc)	Male	71	52.8	134.5	(105.0-169.6)
Female	1	1.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	3.7	nc	(nc-nc)
Male	5	9.6	52.3	(16.9-122.1)	Female	1	2.4	nc	(nc-nc)
Female	5	5.5	90.3	(29.1-210.6)	<u>Testis</u>				
<u>Larynx</u>					Male	2	2.6	nc	(nc-nc)
Male	1	2.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.8	nc	(nc-nc)	Male	6	4.8	125.1	(45.7-272.3)
<u>Leukemia</u>					Female	18	14.0	128.3	(76.0-202.7)
Male	9	6.4	140.2	(64.0-266.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	8	4.9	164.8	(71.0-324.8)	Female	13	16.0	81.4	(43.3-139.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	7	6.0	115.7	(46.4-238.5)	Male	238	207.9	114.5	(100.4-130.0)
Female	2	2.0	nc	(nc-nc)	Female	247	233.5	105.8	(93.0-119.8)
<u>Lung and Bronchus</u>									
Male	31	26.4	117.4	(79.8-166.7)					
Female	40	31.0	128.9	(92.1-175.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Amherst

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	15	18.3	81.9	(45.8-135.0)	Male	13	12.1	107.7	(57.3-184.2)
Female	2	7.2	nc	(nc-nc)	Female	14	11.4	122.5	(66.9-205.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	5.1	nc	(nc-nc)	Male	4	3.6	nc	(nc-nc)
Female	2	4.5	nc	(nc-nc)	Female	1	3.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.6	nc	(nc-nc)	Male	6	11.8	50.9	(18.6-110.8)
Female	77	76.5	100.7	(79.4-125.8)	Female	13	10.7	121.6	(64.7-208.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.7	nc	(nc-nc)	Male	9	8.7	103.5	(47.3-196.6)
<u>Colon / Rectum</u>					Female	3	4.4	nc	(nc-nc)
Male	14	19.6	71.3	(39.0-119.7)	<u>Ovary</u>				
Female	27	20.9	129.2	(85.1-188.0)	Female	9	7.4	122.3	(55.8-232.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	4.6	nc	(nc-nc)	Male	9	6.4	139.8	(63.8-265.5)
Female	0	1.4	nc	(nc-nc)	Female	7	7.1	98.3	(39.4-202.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	4.0	nc	(nc-nc)	Male	42	55.7	75.4	(54.3-101.9)
Female	0	4.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	4.4	nc	(nc-nc)
Male	5	10.1	49.7	(16.0-116.0)	Female	1	2.9	nc	(nc-nc)
Female	7	6.3	110.9	(44.4-228.5)	<u>Testis</u>				
<u>Larynx</u>					Male	1	7.0	nc	(nc-nc)
Male	2	2.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.9	nc	(nc-nc)	Male	7	5.7	123.7	(49.5-254.8)
<u>Leukemia</u>					Female	3	20.3	nc	(nc-nc)
Male	9	9.2	98.0	(44.7-186.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	7.0	nc	(nc-nc)	Female	13	17.3	75.2	(40.0-128.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	6.5	nc	(nc-nc)	Male	169	250.0	67.6	(57.8-78.6)
Female	0	2.5	nc	(nc-nc)	Female	219	278.6	78.6	(68.5-89.7)
<u>Lung and Bronchus</u>									
Male	14	32.6	43.0	(23.5-72.2)					
Female	17	37.3	45.6	(26.5-73.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Andover

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	25	35.1	71.3	(46.1-105.3)	Male	26	22.6	115.0	(75.1-168.5)
Female	9	12.3	73.1	(33.4-138.8)	Female	28	18.1	155.1	(103.0-224.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	8	7.0	114.6	(49.3-225.8)	Male	7	7.4	94.3	(37.8-194.3)
Female	5	5.9	84.6	(27.3-197.5)	Female	12	5.8	207.3	(107.0-362.2)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	1.2	nc	(nc-nc)	Male	29	20.4	142.3	(95.3-204.4)
Female	158	150.2	105.2	(89.4-122.9)	Female	18	17.9	100.4	(59.4-158.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	5.0	nc	(nc-nc)	Male	16	17.5	91.2	(52.1-148.2)
<u>Colon / Rectum</u>					Female	2	7.7	nc	(nc-nc)
Male	31	38.7	80.1	(54.4-113.7)	<u>Ovary</u>				
Female	39	37.3	104.6	(74.4-143.1)	Female	12	12.7	94.2	(48.6-164.6)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	9	9.4	96.0	(43.8-182.2)	Male	13	12.7	102.4	(54.5-175.1)
Female	7	2.4	286.2	(114.7-589.8)	Female	13	12.6	103.3	(54.9-176.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	2.5	nc	(nc-nc)	Male	107	116.6	91.8	(75.2-110.9)
Female	3	2.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	8.6	58.3	(18.8-136.1)
Male	19	20.4	93.0	(55.9-145.2)	Female	4	5.0	nc	(nc-nc)
Female	12	11.6	103.4	(53.4-180.7)	<u>Testis</u>				
<u>Larynx</u>					Male	8	4.3	188.2	(81.0-370.8)
Male	3	5.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	2	1.6	nc	(nc-nc)	Male	14	9.1	153.4	(83.8-257.3)
<u>Leukemia</u>					Female	42	28.0	150.0	(108.1-202.8)
Male	18	14.4	124.8	(73.9-197.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	11	10.4	106.3	(53.0-190.1)	Female	25	33.4	74.9	(48.4-110.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	8	12.8	62.4	(26.9-122.9)	Male	421	466.2	90.3	(81.9-99.4)
Female	2	4.1	nc	(nc-nc)	Female	476	488.4	97.5	(88.9-106.6)
<u>Lung and Bronchus</u>									
Male	40	63.4	63.1	(45.0-85.9)					
Female	40	66.2	60.5	(43.2-82.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Aquinnah

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	3	1.6	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.1	nc	(nc-nc)
Male	1	0.3	nc	(nc-nc)	<u>Ovary</u>				
Female	0	0.3	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.0	nc	(nc-nc)	Male	2	0.9	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.3	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.1	nc	(nc-nc)	Male	4	3.6	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	4	4.9	nc	(nc-nc)
<u>Lung and Bronchus</u>									
Male	0	0.4	nc	(nc-nc)					
Female	0	0.6	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Arlington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	47	45.7	102.9	(75.6-136.8)	Male	27	29.4	91.9	(60.5-133.7)
Female	17	18.4	92.5	(53.8-148.0)	Female	24	25.5	94.1	(60.3-140.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	9	9.0	100.3	(45.8-190.4)	Male	11	9.3	118.1	(58.9-211.4)
Female	9	7.9	114.0	(52.0-216.4)	Female	5	8.4	59.6	(19.2-139.2)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.6	nc	(nc-nc)	Male	19	26.5	71.8	(43.2-112.2)
Female	209	201.8	103.6	(90.0-118.6)	Female	32	25.8	123.9	(84.7-174.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	7.0	71.3	(23.0-166.4)	Male	18	21.6	83.5	(49.5-132.0)
<u>Colon / Rectum</u>					Female	14	10.9	129.0	(70.5-216.4)
Male	44	50.3	87.4	(63.5-117.4)	<u>Ovary</u>				
Female	52	55.0	94.6	(70.7-124.1)	Female	17	17.4	97.5	(56.8-156.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	11	11.5	95.6	(47.6-171.0)	Male	18	16.3	110.4	(65.4-174.4)
Female	3	3.6	nc	(nc-nc)	Female	16	18.9	84.5	(48.3-137.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	3.5	nc	(nc-nc)	Male	136	136.6	99.6	(83.5-117.8)
Female	6	2.9	207.3	(75.7-451.1)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	10	11.1	90.0	(43.1-165.5)
Male	27	25.5	105.9	(69.8-154.1)	Female	7	7.5	93.3	(37.4-192.2)
Female	11	15.9	69.0	(34.4-123.5)	<u>Testis</u>				
<u>Larynx</u>					Male	7	6.7	105.2	(42.2-216.8)
Male	5	6.7	74.8	(24.1-174.6)	<u>Thyroid</u>				
Female	3	2.2	nc	(nc-nc)	Male	13	12.0	108.3	(57.6-185.2)
<u>Leukemia</u>					Female	38	37.8	100.6	(71.2-138.1)
Male	18	18.8	95.7	(56.7-151.3)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	12	15.0	80.2	(41.4-140.1)	Female	46	44.7	103.0	(75.4-137.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	15	15.7	95.7	(53.5-157.9)	Male	558	585.9	95.2	(87.5-103.5)
Female	4	6.0	nc	(nc-nc)	Female	677	682.8	99.2	(91.8-106.9)
<u>Lung and Bronchus</u>									
Male	73	79.7	91.6	(71.8-115.2)					
Female	91	93.7	97.1	(78.2-119.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Ashburnham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	5.0	100.0	(32.2-233.3)	Male	2	3.7	nc	(nc-nc)
Female	0	2.0	nc	(nc-nc)	Female	4	3.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.2	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	3	3.4	nc	(nc-nc)
Female	19	28.0	67.9	(40.9-106.1)	Female	1	3.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.9	nc	(nc-nc)	Male	2	3.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.3	nc	(nc-nc)
Male	4	6.2	nc	(nc-nc)	<u>Ovary</u>				
Female	7	6.0	116.5	(46.7-240.0)	Female	3	2.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	1.6	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	1	2.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.5	nc	(nc-nc)	Male	21	21.2	98.9	(61.2-151.2)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	1.3	nc	(nc-nc)
Male	2	3.7	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
Female	3	2.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.8	nc	(nc-nc)
Male	1	0.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.3	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
<u>Leukemia</u>					Female	4	5.3	nc	(nc-nc)
Male	6	2.3	261.7	(95.5-569.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	1.7	nc	(nc-nc)	Female	4	6.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	2.3	nc	(nc-nc)	Male	71	77.8	91.3	(71.3-115.1)
Female	0	0.7	nc	(nc-nc)	Female	64	86.1	74.3	(57.2-94.9)
<u>Lung and Bronchus</u>									
Male	7	9.6	72.7	(29.1-149.8)					
Female	4	11.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Ashby

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	3.3	nc	(nc-nc)	Male	4	2.3	nc	(nc-nc)
Female	3	1.2	nc	(nc-nc)	Female	3	1.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	0.7	nc	(nc-nc)	Male	3	0.7	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
Female	13	14.7	88.4	(47.0-151.2)	Female	0	1.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.5	nc	(nc-nc)	Male	3	1.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	0.8	nc	(nc-nc)
Male	4	3.9	nc	(nc-nc)	<u>Ovary</u>				
Female	2	3.6	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.9	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.3	nc	(nc-nc)	Male	8	11.3	70.9	(30.5-139.7)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	0.8	nc	(nc-nc)
Male	0	2.0	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.5	nc	(nc-nc)
Male	2	0.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	2	1.0	nc	(nc-nc)
<u>Leukemia</u>					Female	2	2.7	nc	(nc-nc)
Male	0	1.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.0	nc	(nc-nc)	Female	1	3.3	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.3	nc	(nc-nc)	Male	41	45.6	90.0	(64.6-122.1)
Female	2	0.4	nc	(nc-nc)	Female	42	47.4	88.7	(63.9-119.9)
<u>Lung and Bronchus</u>									
Male	3	6.0	nc	(nc-nc)					
Female	3	6.4	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Ashfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	1.5	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.0	nc	(nc-nc)
Female	6	9.6	62.7	(22.9-136.4)	Female	0	1.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	2	1.0	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.5	nc	(nc-nc)
Male	1	1.9	nc	(nc-nc)	<u>Ovary</u>				
Female	3	2.4	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	3	6.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.4	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.2	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.6	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.6	nc	(nc-nc)	Female	4	2.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	0.7	nc	(nc-nc)	Male	18	23.2	77.7	(46.0-122.9)
Female	0	0.3	nc	(nc-nc)	Female	20	31.3	63.8	(39.0-98.6)
<u>Lung and Bronchus</u>									
Male	2	2.8	nc	(nc-nc)					
Female	2	4.4	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Ashland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	18	16.1	112.1	(66.4-177.2)	Male	6	10.9	54.8	(20.0-119.3)
Female	4	6.1	nc	(nc-nc)	Female	3	9.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	3.4	nc	(nc-nc)	Male	4	3.5	nc	(nc-nc)
Female	2	2.9	nc	(nc-nc)	Female	2	2.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.6	nc	(nc-nc)	Male	8	9.8	81.5	(35.1-160.6)
Female	62	73.7	84.1	(64.5-107.9)	Female	6	8.9	67.3	(24.6-146.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.6	nc	(nc-nc)	Male	5	8.8	57.1	(18.4-133.2)
<u>Colon / Rectum</u>					Female	5	3.8	130.5	(42.1-304.6)
Male	11	18.6	59.3	(29.5-106.1)	<u>Ovary</u>				
Female	21	18.2	115.5	(71.5-176.6)	Female	7	6.3	111.5	(44.7-229.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	10	4.4	225.9	(108.2-415.5)	Male	3	6.1	nc	(nc-nc)
Female	4	1.2	nc	(nc-nc)	Female	6	6.2	96.3	(35.2-209.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.3	nc	(nc-nc)	Male	40	56.1	71.3	(51.0-97.2)
Female	2	1.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	6	4.0	148.2	(54.1-322.6)
Male	5	10.0	49.9	(16.1-116.5)	Female	3	2.5	nc	(nc-nc)
Female	1	5.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	4	2.4	nc	(nc-nc)
Male	1	2.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.8	nc	(nc-nc)	Male	3	4.7	nc	(nc-nc)
<u>Leukemia</u>					Female	21	14.0	150.2	(93.0-229.7)
Male	2	6.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	5.2	116.1	(42.4-252.7)	Female	15	16.8	89.1	(49.8-146.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	6.3	79.3	(25.6-185.1)	Male	168	223.0	75.3	(64.4-87.6)
Female	3	2.1	nc	(nc-nc)	Female	224	241.5	92.8	(81.0-105.7)
<u>Lung and Bronchus</u>									
Male	24	29.1	82.3	(52.7-122.5)					
Female	41	32.5	126.1	(90.5-171.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Athol

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	18	14.6	123.4	(73.1-195.1)	Male	6	9.3	64.4	(23.5-140.1)
Female	3	4.4	nc	(nc-nc)	Female	3	6.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	2.8	nc	(nc-nc)	Male	1	3.0	nc	(nc-nc)
Female	0	2.0	nc	(nc-nc)	Female	0	2.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	2	8.2	nc	(nc-nc)
Female	44	49.7	88.5	(64.3-118.8)	Female	5	6.3	79.9	(25.7-186.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.7	nc	(nc-nc)	Male	7	7.1	99.2	(39.7-204.4)
<u>Colon / Rectum</u>					Female	3	2.7	nc	(nc-nc)
Male	17	15.4	110.6	(64.4-177.1)	<u>Ovary</u>				
Female	14	13.0	107.3	(58.6-180.1)	Female	1	4.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	3.9	nc	(nc-nc)	Male	4	5.3	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	5	4.5	110.0	(35.5-256.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.0	nc	(nc-nc)	Male	26	48.1	54.1	(35.3-79.3)
Female	1	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	3.5	nc	(nc-nc)
Male	10	8.2	122.5	(58.7-225.3)	Female	1	1.8	nc	(nc-nc)
Female	4	3.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.7	nc	(nc-nc)
Male	1	2.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.5	nc	(nc-nc)	Male	4	3.6	nc	(nc-nc)
<u>Leukemia</u>					Female	11	9.1	121.2	(60.4-217.0)
Male	2	5.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	3.6	139.5	(45.0-325.6)	Female	20	11.4	175.6	(107.2-271.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	5.4	nc	(nc-nc)	Male	167	191.2	87.3	(74.6-101.6)
Female	2	1.5	nc	(nc-nc)	Female	174	166.7	104.4	(89.4-121.1)
<u>Lung and Bronchus</u>									
Male	37	26.8	138.2	(97.3-190.5)					
Female	32	23.0	138.9	(95.0-196.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Attleboro

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	41	42.0	97.6	(70.1-132.5)	Male	27	27.9	96.7	(63.7-140.7)
Female	17	15.1	112.9	(65.8-180.8)	Female	23	22.3	103.3	(65.4-154.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	8.9	78.7	(31.5-162.2)	Male	6	8.9	67.6	(24.7-147.1)
Female	7	7.2	97.5	(39.1-201.0)	Female	7	7.0	99.9	(40.0-205.7)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.5	nc	(nc-nc)	Male	13	25.1	51.8	(27.6-88.7)
Female	184	179.4	102.5	(88.3-118.5)	Female	17	21.8	78.1	(45.5-125.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	6.3	79.8	(25.7-186.3)	Male	21	21.3	98.6	(61.0-150.7)
<u>Colon / Rectum</u>					Female	12	9.3	128.9	(66.5-225.1)
Male	55	47.2	116.5	(87.8-151.7)	<u>Ovary</u>				
Female	46	45.0	102.3	(74.9-136.5)	Female	22	15.4	143.2	(89.7-216.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	13	11.1	116.8	(62.1-199.8)	Male	21	15.3	137.4	(85.0-210.1)
Female	5	3.0	168.2	(54.2-392.5)	Female	17	15.2	111.5	(64.9-178.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	7	3.6	191.9	(76.9-395.3)	Male	142	136.1	104.3	(87.9-123.0)
Female	2	2.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	10.4	48.2	(15.5-112.5)
Male	17	25.0	68.0	(39.6-108.8)	Female	8	6.1	131.6	(56.7-259.4)
Female	12	14.0	85.6	(44.2-149.6)	<u>Testis</u>				
<u>Larynx</u>					Male	10	6.9	145.0	(69.4-266.7)
Male	10	6.5	153.8	(73.6-282.8)	<u>Thyroid</u>				
Female	3	2.0	nc	(nc-nc)	Male	10	12.0	83.2	(39.8-153.0)
<u>Leukemia</u>					Female	24	35.1	68.3	(43.8-101.6)
Male	15	17.9	83.9	(46.9-138.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	8	12.8	62.5	(26.9-123.3)	Female	48	40.0	120.1	(88.6-159.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	11	15.3	72.1	(35.9-128.9)	Male	571	563.2	101.4	(93.2-110.1)
Female	11	5.1	216.2	(107.8-386.8)	Female	614	591.6	103.8	(95.7-112.3)
<u>Lung and Bronchus</u>									
Male	99	75.6	131.0	(106.5-159.5)					
Female	78	80.5	96.9	(76.6-120.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Auburn

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	27	19.4	139.2	(91.7-202.6)	Male	15	12.0	124.7	(69.8-205.8)
Female	11	8.0	137.0	(68.3-245.2)	Female	11	10.3	106.9	(53.3-191.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	3.5	nc	(nc-nc)	Male	5	3.9	127.3	(41.0-297.1)
Female	4	3.2	nc	(nc-nc)	Female	8	3.6	221.7	(95.4-436.8)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.7	nc	(nc-nc)	Male	11	10.9	101.3	(50.5-181.2)
Female	83	83.5	99.5	(79.2-123.3)	Female	13	11.0	118.3	(62.9-202.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	2.6	nc	(nc-nc)	Male	11	8.8	124.7	(62.2-223.1)
<u>Colon / Rectum</u>					Female	1	4.6	nc	(nc-nc)
Male	20	20.8	96.2	(58.7-148.5)	<u>Ovary</u>				
Female	20	23.6	84.8	(51.8-130.9)	Female	7	7.2	96.7	(38.7-199.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	4.9	123.1	(44.9-267.9)	Male	6	6.9	87.6	(32.0-190.6)
Female	1	1.6	nc	(nc-nc)	Female	6	8.3	72.5	(26.5-157.8)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.2	nc	(nc-nc)	Male	56	58.7	95.4	(72.1-123.9)
Female	3	1.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	4.6	nc	(nc-nc)
Male	10	10.5	95.6	(45.7-175.7)	Female	4	3.2	nc	(nc-nc)
Female	5	6.6	75.2	(24.2-175.6)	<u>Testis</u>				
<u>Larynx</u>					Male	3	2.1	nc	(nc-nc)
Male	8	2.8	281.8	(121.4-555.4)	<u>Thyroid</u>				
Female	0	1.0	nc	(nc-nc)	Male	5	4.6	109.6	(35.3-255.7)
<u>Leukemia</u>					Female	13	14.2	91.6	(48.7-156.6)
Male	7	7.6	92.1	(36.9-189.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	6.2	96.3	(35.2-209.7)	Female	22	18.4	119.4	(74.8-180.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	7	6.4	108.7	(43.5-224.0)	Male	266	244.4	108.8	(96.1-122.7)
Female	0	2.5	nc	(nc-nc)	Female	282	285.8	98.7	(87.5-110.9)
<u>Lung and Bronchus</u>									
Male	37	34.2	108.0	(76.1-148.9)					
Female	39	40.8	95.6	(68.0-130.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Avon

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	5.2	171.8	(78.4-326.2)	Male	5	3.2	154.1	(49.7-359.6)
Female	1	2.0	nc	(nc-nc)	Female	3	2.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.0	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.2	nc	(nc-nc)	Male	8	2.9	273.4	(117.7-538.7)
Female	26	21.8	119.5	(78.1-175.1)	Female	3	2.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.7	nc	(nc-nc)	Male	0	2.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.2	nc	(nc-nc)
Male	5	5.6	88.9	(28.7-207.6)	<u>Ovary</u>				
Female	5	5.6	88.8	(28.6-207.1)	Female	3	1.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	1.4	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	2	2.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	0.4	nc	(nc-nc)	Male	9	16.9	53.4	(24.4-101.4)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	1.2	nc	(nc-nc)
Male	3	2.9	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
Female	2	1.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.6	nc	(nc-nc)
Male	1	0.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	3	1.3	nc	(nc-nc)
<u>Leukemia</u>					Female	3	3.7	nc	(nc-nc)
Male	3	2.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.6	nc	(nc-nc)	Female	2	5.0	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	1.8	275.0	(88.6-641.7)	Male	78	67.4	115.8	(91.5-144.5)
Female	0	0.7	nc	(nc-nc)	Female	74	73.6	100.6	(79.0-126.3)
<u>Lung and Bronchus</u>									
Male	12	9.2	130.8	(67.5-228.5)					
Female	14	10.9	128.6	(70.2-215.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Ayer

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	6.6	105.5	(42.2-217.3)	Male	1	4.7	nc	(nc-nc)
Female	4	2.5	nc	(nc-nc)	Female	3	3.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.5	nc	(nc-nc)	Male	2	1.5	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	4.2	nc	(nc-nc)
Female	35	29.9	117.2	(81.6-163.0)	Female	4	3.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.1	nc	(nc-nc)	Male	3	3.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	1.5	nc	(nc-nc)
Male	6	7.7	78.3	(28.6-170.5)	<u>Ovary</u>				
Female	11	7.6	145.0	(72.3-259.6)	Female	3	2.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	1.8	325.3	(118.8-708.0)	Male	4	2.5	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	4	2.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.6	nc	(nc-nc)	Male	20	22.2	90.1	(55.0-139.1)
Female	1	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	1.7	nc	(nc-nc)
Male	2	4.2	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
Female	4	2.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.2	nc	(nc-nc)
Male	1	1.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
<u>Leukemia</u>					Female	4	6.3	nc	(nc-nc)
Male	3	2.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	2.1	nc	(nc-nc)	Female	12	6.2	192.3	(99.3-336.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	2.6	nc	(nc-nc)	Male	87	93.0	93.5	(74.9-115.4)
Female	1	0.8	nc	(nc-nc)	Female	121	98.8	122.5	(101.6-146.4)
<u>Lung and Bronchus</u>									
Male	18	12.4	145.1	(86.0-229.4)					
Female	19	13.5	140.3	(84.4-219.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Barnstable

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	98	68.4	143.3	(116.3-174.6)	Male	60	41.1	145.9	(111.4-187.8)
Female	28	23.4	119.7	(79.5-172.9)	Female	44	28.9	152.3	(110.7-204.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	14	11.4	122.7	(67.0-205.9)	Male	9	13.4	66.9	(30.5-127.0)
Female	10	9.2	108.6	(52.0-199.8)	Female	13	10.5	124.4	(66.2-212.7)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	2.3	nc	(nc-nc)	Male	46	36.6	125.6	(91.9-167.5)
Female	312	242.9	128.4	(114.6-143.5)	Female	43	31.4	136.8	(99.0-184.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	8	7.1	113.3	(48.8-223.3)	Male	32	29.8	107.2	(73.3-151.4)
<u>Colon / Rectum</u>					Female	16	13.1	121.9	(69.6-197.9)
Male	59	69.5	84.9	(64.6-109.6)	<u>Ovary</u>				
Female	60	64.8	92.6	(70.6-119.1)	Female	21	21.0	99.9	(61.8-152.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	21	17.2	122.4	(75.7-187.1)	Male	31	23.9	129.6	(88.1-184.0)
Female	4	4.6	nc	(nc-nc)	Female	19	23.5	80.9	(48.7-126.3)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	3.9	nc	(nc-nc)	Male	236	209.4	112.7	(98.8-128.0)
Female	0	3.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	18	16.0	112.4	(66.6-177.7)
Male	32	35.1	91.1	(62.3-128.6)	Female	10	8.8	113.5	(54.3-208.8)
Female	19	19.8	95.8	(57.7-149.7)	<u>Testis</u>				
<u>Larynx</u>					Male	7	6.2	113.8	(45.6-234.5)
Male	6	9.9	60.5	(22.1-131.7)	<u>Thyroid</u>				
Female	0	2.8	nc	(nc-nc)	Male	10	14.2	70.2	(33.6-129.1)
<u>Leukemia</u>					Female	28	38.3	73.2	(48.6-105.8)
Male	30	26.0	115.6	(77.9-165.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	27	17.6	153.3	(101.0-223.1)	Female	43	56.0	76.8	(55.6-103.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	27	22.6	119.3	(78.6-173.5)	Male	919	846.8	108.5	(101.6-115.8)
Female	6	7.6	79.1	(28.9-172.1)	Female	885	826.5	107.1	(100.1-114.4)
<u>Lung and Bronchus</u>									
Male	91	121.6	74.8	(60.3-91.9)					
Female	111	124.7	89.0	(73.2-107.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Barre

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	5.0	120.4	(44.0-262.1)	Male	3	3.4	nc	(nc-nc)
Female	2	2.0	nc	(nc-nc)	Female	4	2.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.1	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	2	0.9	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	2	3.1	nc	(nc-nc)
Female	17	23.4	72.7	(42.3-116.3)	Female	0	2.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.8	nc	(nc-nc)	Male	2	2.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.2	nc	(nc-nc)
Male	10	5.8	172.6	(82.6-317.4)	<u>Ovary</u>				
Female	2	6.2	nc	(nc-nc)	Female	2	2.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.4	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	1	2.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.5	nc	(nc-nc)	Male	16	18.0	89.0	(50.8-144.5)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.3	nc	(nc-nc)
Male	2	3.1	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
Female	2	1.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.8	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
<u>Leukemia</u>					Female	1	4.2	nc	(nc-nc)
Male	0	2.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	1.7	nc	(nc-nc)	Female	7	5.2	133.6	(53.5-275.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.9	nc	(nc-nc)	Male	60	69.9	85.8	(65.5-110.5)
Female	0	0.7	nc	(nc-nc)	Female	61	77.6	78.6	(60.1-101.0)
<u>Lung and Bronchus</u>									
Male	7	8.9	78.6	(31.5-162.0)					
Female	6	10.5	57.3	(20.9-124.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Becket

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	3.2	158.5	(51.1-369.8)	Male	1	1.9	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.5	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
Female	9	10.4	86.4	(39.4-164.1)	Female	2	1.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.5	nc	(nc-nc)
Male	5	3.1	159.2	(51.3-371.5)	<u>Ovary</u>				
Female	2	2.5	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	0.8	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	4	9.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	0.7	nc	(nc-nc)
Male	1	1.6	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.2	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Leukemia</u>					Female	1	1.7	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.7	nc	(nc-nc)	Female	4	2.4	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.0	nc	(nc-nc)	Male	33	38.1	86.7	(59.7-121.8)
Female	0	0.3	nc	(nc-nc)	Female	27	33.9	79.7	(52.5-115.9)
<u>Lung and Bronchus</u>									
Male	5	5.6	88.5	(28.5-206.6)					
Female	5	5.0	100.9	(32.5-235.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Bedford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	18	18.0	100.2	(59.3-158.3)	Male	14	10.8	129.0	(70.5-216.5)
Female	5	6.0	83.5	(26.9-194.9)	Female	4	7.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	3.1	159.8	(51.5-372.9)	Male	5	3.5	144.7	(46.6-337.8)
Female	0	2.5	nc	(nc-nc)	Female	2	2.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.6	nc	(nc-nc)	Male	15	9.7	155.3	(86.8-256.1)
Female	67	62.9	106.5	(82.5-135.2)	Female	9	8.2	110.1	(50.2-208.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	2.0	nc	(nc-nc)	Male	8	7.4	107.8	(46.4-212.4)
<u>Colon / Rectum</u>					Female	4	3.4	nc	(nc-nc)
Male	15	18.7	80.4	(45.0-132.6)	<u>Ovary</u>				
Female	15	17.7	84.9	(47.5-140.1)	Female	1	5.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	4.2	nc	(nc-nc)	Male	8	6.1	130.4	(56.2-257.0)
Female	2	1.1	nc	(nc-nc)	Female	7	6.1	114.8	(46.0-236.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.1	nc	(nc-nc)	Male	58	45.9	126.3	(95.9-163.3)
Female	0	0.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	6	4.2	142.5	(52.0-310.2)
Male	8	8.8	90.5	(39.0-178.3)	Female	4	2.4	nc	(nc-nc)
Female	2	5.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.9	nc	(nc-nc)
Male	1	2.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.7	nc	(nc-nc)	Male	1	3.9	nc	(nc-nc)
<u>Leukemia</u>					Female	11	11.0	100.1	(49.9-179.0)
Male	10	7.0	142.5	(68.2-262.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	7	4.8	147.3	(59.0-303.5)	Female	6	13.6	44.2	(16.1-96.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	5.6	nc	(nc-nc)	Male	226	212.5	106.4	(92.9-121.2)
Female	1	1.9	nc	(nc-nc)	Female	187	214.8	87.1	(75.0-100.5)
<u>Lung and Bronchus</u>									
Male	28	30.9	90.7	(60.2-131.1)					
Female	26	30.6	84.9	(55.5-124.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Belchertown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	14.5	68.8	(32.9-126.5)	Male	6	10.0	60.1	(21.9-130.8)
Female	3	4.5	nc	(nc-nc)	Female	6	7.3	82.1	(30.0-178.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	3.2	189.8	(69.3-413.1)	Male	5	3.2	155.2	(50.0-362.2)
Female	1	2.4	nc	(nc-nc)	Female	2	2.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	9	8.9	101.3	(46.2-192.3)
Female	71	61.2	116.0	(90.6-146.3)	Female	15	6.9	217.6	(121.7-358.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.2	nc	(nc-nc)	Male	7	8.2	85.6	(34.3-176.4)
<u>Colon / Rectum</u>					Female	5	3.0	165.3	(53.3-385.7)
Male	15	16.7	89.8	(50.2-148.1)	<u>Ovary</u>				
Female	19	13.8	138.0	(83.1-215.5)	Female	5	5.1	97.7	(31.5-227.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	4.2	nc	(nc-nc)	Male	4	5.6	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	6	4.5	132.2	(48.3-287.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.2	nc	(nc-nc)	Male	48	54.5	88.0	(64.9-116.7)
Female	0	0.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	6	3.7	162.1	(59.2-352.7)
Male	8	9.3	85.8	(36.9-169.1)	Female	5	1.8	271.7	(87.6-634.1)
Female	2	4.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	3	2.0	nc	(nc-nc)
Male	2	2.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.6	nc	(nc-nc)	Male	1	4.3	nc	(nc-nc)
<u>Leukemia</u>					Female	9	12.1	74.2	(33.9-140.9)
Male	6	6.2	96.8	(35.3-210.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	3.9	nc	(nc-nc)	Female	20	13.9	144.2	(88.1-222.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	6.0	nc	(nc-nc)	Male	164	207.5	79.0	(67.4-92.1)
Female	2	1.6	nc	(nc-nc)	Female	209	192.7	108.5	(94.3-124.2)
<u>Lung and Bronchus</u>									
Male	14	27.7	50.6	(27.6-84.9)					
Female	20	25.0	80.1	(48.9-123.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Bellingham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	14.4	76.5	(38.1-136.9)	Male	10	10.2	98.1	(47.0-180.5)
Female	3	5.8	nc	(nc-nc)	Female	9	8.7	102.9	(47.0-195.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	3.2	nc	(nc-nc)	Male	6	3.2	184.9	(67.5-402.4)
Female	4	2.8	nc	(nc-nc)	Female	1	2.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.5	nc	(nc-nc)	Male	19	9.1	209.3	(125.9-326.8)
Female	69	71.5	96.4	(75.0-122.1)	Female	12	8.4	142.2	(73.4-248.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.5	nc	(nc-nc)	Male	7	8.4	83.5	(33.5-172.1)
<u>Colon / Rectum</u>					Female	2	3.6	nc	(nc-nc)
Male	21	17.1	122.5	(75.8-187.3)	<u>Ovary</u>				
Female	20	16.9	118.3	(72.2-182.7)	Female	3	6.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	7	4.1	169.0	(67.7-348.2)	Male	6	5.5	108.9	(39.8-237.1)
Female	2	1.2	nc	(nc-nc)	Female	8	5.9	136.5	(58.8-269.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.3	nc	(nc-nc)	Male	73	52.7	138.5	(108.5-174.1)
Female	1	1.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	3.7	135.0	(43.5-315.0)
Male	8	9.5	84.3	(36.3-166.2)	Female	1	2.3	nc	(nc-nc)
Female	5	5.6	89.9	(29.0-209.9)	<u>Testis</u>				
<u>Larynx</u>					Male	2	2.5	nc	(nc-nc)
Male	1	2.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.8	nc	(nc-nc)	Male	4	4.6	nc	(nc-nc)
<u>Leukemia</u>					Female	16	13.9	114.9	(65.6-186.6)
Male	5	6.3	79.5	(25.6-185.6)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	4.9	nc	(nc-nc)	Female	17	16.3	104.4	(60.8-167.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	6	6.0	99.4	(36.3-216.4)	Male	246	207.3	118.7	(104.3-134.5)
Female	0	2.0	nc	(nc-nc)	Female	211	232.1	90.9	(79.1-104.1)
<u>Lung and Bronchus</u>									
Male	31	26.7	116.3	(79.0-165.0)					
Female	22	31.4	70.0	(43.9-106.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Belmont

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	22	28.2	78.1	(48.9-118.3)	Male	16	17.5	91.5	(52.3-148.6)
Female	3	10.1	nc	(nc-nc)	Female	6	13.9	43.2	(15.8-94.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	5.2	114.7	(41.9-249.6)	Male	4	5.6	nc	(nc-nc)
Female	4	4.5	nc	(nc-nc)	Female	4	4.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	4	1.0	nc	(nc-nc)	Male	18	15.8	113.9	(67.5-180.0)
Female	125	111.3	112.3	(93.4-133.8)	Female	8	14.1	56.7	(24.4-111.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	3.8	nc	(nc-nc)	Male	5	12.6	39.7	(12.8-92.6)
<u>Colon / Rectum</u>					Female	6	5.9	101.6	(37.1-221.0)
Male	21	30.0	69.9	(43.2-106.8)	<u>Ovary</u>				
Female	23	29.8	77.3	(49.0-115.9)	Female	13	9.5	136.2	(72.5-233.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	7.0	71.7	(23.1-167.3)	Male	12	9.9	121.5	(62.7-212.2)
Female	6	2.0	307.6	(112.3-669.6)	Female	11	10.3	107.0	(53.3-191.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.9	nc	(nc-nc)	Male	76	82.7	91.9	(72.4-115.1)
Female	1	1.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	6.7	74.5	(24.0-173.9)
Male	12	15.0	79.9	(41.2-139.6)	Female	7	4.0	173.7	(69.6-358.0)
Female	3	8.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	6	3.5	173.1	(63.2-376.7)
Male	2	4.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.2	nc	(nc-nc)	Male	8	6.7	119.1	(51.3-234.6)
<u>Leukemia</u>					Female	20	20.8	96.2	(58.7-148.5)
Male	4	11.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	8.2	60.7	(19.5-141.6)	Female	26	24.5	106.3	(69.4-155.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	9.2	nc	(nc-nc)	Male	289	352.1	82.1	(72.9-92.1)
Female	3	3.3	nc	(nc-nc)	Female	334	375.3	89.0	(79.7-99.1)
<u>Lung and Bronchus</u>									
Male	33	49.0	67.4	(46.4-94.7)					
Female	35	52.3	67.0	(46.6-93.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Berkley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	6.6	nc	(nc-nc)	Male	5	4.4	114.0	(36.7-266.0)
Female	0	1.5	nc	(nc-nc)	Female	6	2.8	216.4	(79.0-471.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.4	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	3.9	nc	(nc-nc)
Female	27	23.3	116.1	(76.5-168.9)	Female	6	2.4	247.0	(90.2-537.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	0.9	nc	(nc-nc)	Male	4	3.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.1	nc	(nc-nc)
Male	10	7.2	138.2	(66.1-254.1)	<u>Ovary</u>				
Female	6	4.8	124.6	(45.5-271.2)	Female	0	1.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	1.8	nc	(nc-nc)	Male	1	2.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.5	nc	(nc-nc)	Male	18	22.1	81.5	(48.3-128.8)
Female	1	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.6	nc	(nc-nc)
Male	3	4.0	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.9	nc	(nc-nc)
Male	1	1.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	3	1.8	nc	(nc-nc)
<u>Leukemia</u>					Female	5	5.1	97.6	(31.4-227.7)
Male	3	2.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	1.4	nc	(nc-nc)	Female	9	5.1	178.2	(81.3-338.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	2.5	nc	(nc-nc)	Male	73	89.3	81.8	(64.1-102.8)
Female	0	0.6	nc	(nc-nc)	Female	88	70.7	124.6	(99.9-153.5)
<u>Lung and Bronchus</u>									
Male	11	12.4	88.8	(44.3-158.9)					
Female	9	8.5	105.6	(48.2-200.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Berlin

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	4.2	nc	(nc-nc)	Male	6	2.5	238.1	(87.0-518.3)
Female	2	1.2	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.7	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.1	nc	(nc-nc)	Male	0	2.3	nc	(nc-nc)
Female	12	13.8	87.2	(45.0-152.3)	Female	1	1.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.4	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.7	nc	(nc-nc)
Male	3	4.4	nc	(nc-nc)	<u>Ovary</u>				
Female	2	3.4	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	1.0	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	0.3	nc	(nc-nc)	Male	10	12.3	81.3	(38.9-149.6)
Female	1	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.0	nc	(nc-nc)
Male	3	2.2	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	0.5	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
<u>Leukemia</u>					Female	4	2.3	nc	(nc-nc)
Male	0	1.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.9	nc	(nc-nc)	Female	5	3.1	160.5	(51.7-374.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.3	nc	(nc-nc)	Male	55	51.4	106.9	(80.5-139.2)
Female	0	0.4	nc	(nc-nc)	Female	39	44.6	87.4	(62.1-119.4)
<u>Lung and Bronchus</u>									
Male	8	7.2	111.7	(48.1-220.2)					
Female	5	6.3	79.4	(25.6-185.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Bernardston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	3.7	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	Female	4	1.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.6	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	2	0.4	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	5	1.9	257.8	(83.1-601.7)
Female	10	12.1	82.5	(39.5-151.7)	Female	3	1.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.4	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.6	nc	(nc-nc)
Male	2	3.8	nc	(nc-nc)	<u>Ovary</u>				
Female	2	3.0	nc	(nc-nc)	Female	2	1.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	0.9	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.2	nc	(nc-nc)	Male	14	10.6	131.9	(72.1-221.3)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	0.9	nc	(nc-nc)
Male	0	1.8	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.3	nc	(nc-nc)
Male	1	0.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
<u>Leukemia</u>					Female	1	1.9	nc	(nc-nc)
Male	1	1.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.8	nc	(nc-nc)	Female	2	2.8	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.1	nc	(nc-nc)	Male	40	43.9	91.1	(65.1-124.0)
Female	1	0.4	nc	(nc-nc)	Female	36	40.0	89.9	(63.0-124.5)
<u>Lung and Bronchus</u>									
Male	6	6.3	95.5	(34.9-207.9)					
Female	4	5.9	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Beverly

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	52	42.5	122.3	(91.3-160.4)	Male	40	26.8	149.1	(106.5-203.0)
Female	22	16.4	134.3	(84.1-203.3)	Female	31	22.8	136.0	(92.4-193.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	13	8.1	159.6	(84.9-272.9)	Male	10	8.6	116.9	(56.0-215.0)
Female	6	7.2	83.1	(30.4-181.0)	Female	6	7.5	80.2	(29.3-174.5)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	4	1.4	nc	(nc-nc)	Male	24	24.0	99.8	(63.9-148.5)
Female	180	180.9	99.5	(85.5-115.2)	Female	19	23.0	82.6	(49.7-128.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	6.0	83.3	(26.8-194.3)	Male	29	20.0	145.1	(97.2-208.5)
<u>Colon / Rectum</u>					Female	12	9.7	123.1	(63.5-215.1)
Male	33	45.7	72.2	(49.7-101.4)	<u>Ovary</u>				
Female	49	48.1	101.8	(75.3-134.6)	Female	15	15.7	95.3	(53.3-157.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	12	10.8	110.8	(57.2-193.5)	Male	17	15.1	112.8	(65.7-180.6)
Female	5	3.3	153.8	(49.6-358.9)	Female	17	16.9	100.5	(58.5-161.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	3.3	nc	(nc-nc)	Male	158	130.8	120.8	(102.7-141.1)
Female	0	3.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	10.2	nc	(nc-nc)
Male	28	23.3	120.3	(79.9-173.8)	Female	4	6.6	nc	(nc-nc)
Female	18	14.3	126.0	(74.6-199.1)	<u>Testis</u>				
<u>Larynx</u>					Male	8	5.8	136.9	(58.9-269.7)
Male	9	6.2	144.7	(66.1-274.8)	<u>Thyroid</u>				
Female	3	2.1	nc	(nc-nc)	Male	12	10.6	113.2	(58.4-197.8)
<u>Leukemia</u>					Female	30	33.9	88.4	(59.7-126.2)
Male	27	17.2	156.7	(103.2-228.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	20	13.3	150.5	(91.9-232.4)	Female	38	40.7	93.4	(66.1-128.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	14	14.6	95.7	(52.3-160.5)	Male	636	544.3	116.8	(107.9-126.3)
Female	9	5.4	168.1	(76.7-319.2)	Female	653	611.7	106.7	(98.7-115.3)
<u>Lung and Bronchus</u>									
Male	85	74.7	113.7	(90.8-140.6)					
Female	89	85.1	104.6	(84.0-128.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Billerica

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	56	40.2	139.2	(105.2-180.8)	Male	28	27.2	102.9	(68.3-148.7)
Female	15	13.6	110.5	(61.8-182.2)	Female	23	20.7	111.2	(70.5-166.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	13	8.6	151.7	(80.7-259.5)	Male	11	8.7	125.8	(62.7-225.1)
Female	5	6.7	75.2	(24.2-175.5)	Female	6	6.4	94.2	(34.4-205.1)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.5	nc	(nc-nc)	Male	23	24.4	94.1	(59.6-141.2)
Female	177	168.0	105.3	(90.4-122.1)	Female	19	19.9	95.5	(57.5-149.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	5.9	84.3	(27.2-196.7)	Male	18	21.6	83.4	(49.4-131.9)
<u>Colon / Rectum</u>					Female	10	8.5	117.6	(56.3-216.3)
Male	38	46.4	81.9	(58.0-112.5)	<u>Ovary</u>				
Female	57	40.6	140.5	(106.4-182.1)	Female	12	14.1	84.8	(43.8-148.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	10	11.1	90.2	(43.2-165.9)	Male	13	14.9	87.5	(46.5-149.6)
Female	2	2.7	nc	(nc-nc)	Female	9	13.9	64.9	(29.6-123.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	6	3.5	171.1	(62.5-372.5)	Male	130	139.4	93.2	(77.9-110.7)
Female	1	2.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	9	10.1	89.4	(40.8-169.8)
Male	29	24.9	116.3	(77.9-167.1)	Female	8	5.5	146.3	(63.0-288.3)
Female	8	12.9	61.9	(26.6-121.9)	<u>Testis</u>				
<u>Larynx</u>					Male	5	6.6	76.0	(24.5-177.4)
Male	2	6.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.8	nc	(nc-nc)	Male	15	12.0	125.0	(69.9-206.1)
<u>Leukemia</u>					Female	35	33.2	105.4	(73.4-146.6)
Male	28	17.0	164.3	(109.1-237.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	19	11.5	164.6	(99.1-257.1)	Female	39	37.1	105.1	(74.7-143.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	12	15.4	78.1	(40.3-136.5)	Male	567	555.5	102.1	(93.8-110.8)
Female	2	4.6	nc	(nc-nc)	Female	593	545.6	108.7	(100.1-117.8)
<u>Lung and Bronchus</u>									
Male	79	72.7	108.7	(86.0-135.5)					
Female	106	73.4	144.3	(118.2-174.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Blackstone

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	7.2	153.1	(76.3-274.0)	Male	6	5.2	115.4	(42.2-251.3)
Female	4	3.0	nc	(nc-nc)	Female	6	4.8	124.1	(45.3-270.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	1.7	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
Female	0	1.5	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.3	nc	(nc-nc)	Male	4	4.6	nc	(nc-nc)
Female	28	39.7	70.5	(46.8-101.9)	Female	3	4.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.4	nc	(nc-nc)	Male	2	4.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	4	2.0	nc	(nc-nc)
Male	9	8.8	102.2	(46.7-194.1)	<u>Ovary</u>				
Female	7	9.6	72.8	(29.2-150.0)	Female	5	3.3	149.4	(48.2-348.7)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	2.1	286.9	(104.8-624.5)	Male	1	2.8	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	3	3.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	0.7	nc	(nc-nc)	Male	26	26.3	98.8	(64.5-144.8)
Female	1	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	1.9	nc	(nc-nc)
Male	2	4.9	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
Female	4	2.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	3	1.3	nc	(nc-nc)
Male	2	1.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	2	2.4	nc	(nc-nc)
<u>Leukemia</u>					Female	3	7.9	nc	(nc-nc)
Male	4	3.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	2.6	229.8	(83.9-500.2)	Female	7	8.7	80.1	(32.1-165.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	3.1	nc	(nc-nc)	Male	117	105.0	111.5	(92.2-133.6)
Female	0	1.0	nc	(nc-nc)	Female	111	126.7	87.6	(72.1-105.5)
<u>Lung and Bronchus</u>									
Male	18	13.3	135.5	(80.2-214.1)					
Female	11	16.0	68.7	(34.2-122.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Blandford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	1.3	nc	(nc-nc)	Male	3	0.9	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	4	5.5	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.2	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.3	nc	(nc-nc)
Male	0	1.6	nc	(nc-nc)	<u>Ovary</u>				
Female	2	1.2	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.4	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	6	5.4	112.1	(40.9-244.0)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	0.3	nc	(nc-nc)
Male	1	0.9	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	1	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Leukemia</u>					Female	1	1.0	nc	(nc-nc)
Male	2	0.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.3	nc	(nc-nc)	Female	2	1.3	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.6	nc	(nc-nc)	Male	19	19.3	98.6	(59.3-154.0)
Female	0	0.1	nc	(nc-nc)	Female	17	17.0	99.7	(58.1-159.7)
<u>Lung and Bronchus</u>									
Male	2	2.4	nc	(nc-nc)					
Female	2	2.2	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Bolton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	4.8	nc	(nc-nc)	Male	1	3.3	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	1	2.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.0	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	5	3.0	168.7	(54.4-393.7)
Female	28	19.4	144.6	(96.1-209.0)	Female	1	2.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.7	nc	(nc-nc)	Male	3	2.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.9	nc	(nc-nc)
Male	5	5.7	87.4	(28.2-203.8)	<u>Ovary</u>				
Female	5	3.9	128.8	(41.5-300.6)	Female	3	1.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.3	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.4	nc	(nc-nc)	Male	21	16.6	126.5	(78.3-193.4)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.2	nc	(nc-nc)
Male	3	3.1	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.7	nc	(nc-nc)
Male	1	0.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
<u>Leukemia</u>					Female	4	4.1	nc	(nc-nc)
Male	2	2.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	1.1	nc	(nc-nc)	Female	8	4.3	186.7	(80.4-367.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.9	nc	(nc-nc)	Male	58	67.0	86.6	(65.7-111.9)
Female	0	0.5	nc	(nc-nc)	Female	60	57.8	103.9	(79.3-133.7)
<u>Lung and Bronchus</u>									
Male	2	8.8	nc	(nc-nc)					
Female	5	7.0	71.8	(23.1-167.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Boston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	338	462.6	73.1	(65.5-81.3)	Male	249	315.3	79.0	(69.5-89.4)
Female	143	181.6	78.8	(66.4-92.8)	Female	205	290.5	70.6	(61.2-80.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	74	109.4	67.6	(53.1-84.9)	Male	107	96.7	110.7	(90.7-133.8)
Female	71	93.2	76.1	(59.5-96.1)	Female	124	83.6	148.3	(123.3-176.8)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	15	16.4	91.7	(51.3-151.2)	Male	265	285.3	92.9	(82.0-104.8)
Female	1909	2115.3	90.2	(86.2-94.4)	Female	252	267.3	94.3	(83.0-106.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	88	83.2	105.8	(84.8-130.3)	Male	265	232.9	113.8	(100.5-128.3)
<u>Colon / Rectum</u>					Female	107	111.7	95.8	(78.5-115.7)
Male	557	519.1	107.3	(98.6-116.6)	<u>Ovary</u>				
Female	581	542.1	107.2	(98.6-116.3)	Female	187	185.7	100.7	(86.8-116.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	122	120.9	100.9	(83.8-120.5)	Male	163	167.1	97.5	(83.1-113.7)
Female	32	35.6	89.8	(61.4-126.7)	Female	176	184.2	95.5	(81.9-110.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	58	58.4	99.4	(75.4-128.5)	Male	1787	1465.8	121.9	(116.3-127.7)
Female	32	51.5	62.2	(42.5-87.8)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	173	114.2	151.5	(129.8-175.9)
Male	235	274.4	85.6	(75.0-97.3)	Female	118	73.9	159.8	(132.2-191.3)
Female	170	167.4	101.6	(86.9-118.0)	<u>Testis</u>				
<u>Larynx</u>					Male	102	119.3	85.5	(69.7-103.8)
Male	90	70.3	128.0	(102.9-157.3)	<u>Thyroid</u>				
Female	17	22.6	75.3	(43.9-120.6)	Male	149	145.5	102.4	(86.6-120.2)
<u>Leukemia</u>					Female	451	490.0	92.0	(83.7-100.9)
Male	174	206.6	84.2	(72.2-97.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	145	162.3	89.3	(75.4-105.1)	Female	435	464.2	93.7	(85.1-102.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	257	165.8	155.0	(136.6-175.1)	Male	6570	6276.4	104.7	(102.2-107.2)
Female	95	60.9	155.9	(126.1-190.6)	Female	6789	7191.1	94.4	(92.2-96.7)
<u>Lung and Bronchus</u>									
Male	874	820.0	106.6	(99.6-113.9)					
Female	875	953.2	91.8	(85.8-98.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Bourne

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	38	29.7	127.9	(90.5-175.6)	Male	25	17.6	142.1	(91.9-209.8)
Female	9	10.9	82.7	(37.7-156.9)	Female	14	13.0	108.0	(59.0-181.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	4.9	nc	(nc-nc)	Male	9	5.8	154.4	(70.4-293.1)
Female	2	4.1	nc	(nc-nc)	Female	4	4.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.0	nc	(nc-nc)	Male	13	15.8	82.2	(43.7-140.5)
Female	87	107.0	81.3	(65.1-100.3)	Female	8	14.4	55.5	(23.9-109.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	3.1	nc	(nc-nc)	Male	16	12.5	128.5	(73.4-208.6)
<u>Colon / Rectum</u>					Female	6	6.0	100.7	(36.8-219.2)
Male	26	30.0	86.5	(56.5-126.8)	<u>Ovary</u>				
Female	28	30.8	91.0	(60.5-131.5)	Female	12	9.4	128.2	(66.2-224.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	12	7.3	165.0	(85.2-288.2)	Male	8	10.2	78.2	(33.7-154.0)
Female	4	2.1	nc	(nc-nc)	Female	9	11.1	81.1	(37.0-154.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.7	nc	(nc-nc)	Male	85	86.2	98.6	(78.8-122.0)
Female	0	1.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	7	6.9	101.3	(40.6-208.7)
Male	10	14.8	67.7	(32.4-124.5)	Female	5	4.2	118.8	(38.3-277.3)
Female	8	8.8	91.0	(39.2-179.3)	<u>Testis</u>				
<u>Larynx</u>					Male	2	2.7	nc	(nc-nc)
Male	10	4.2	237.1	(113.5-436.0)	<u>Thyroid</u>				
Female	4	1.3	nc	(nc-nc)	Male	4	6.0	nc	(nc-nc)
<u>Leukemia</u>					Female	21	16.5	127.0	(78.6-194.1)
Male	5	11.2	44.7	(14.4-104.3)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	8.1	61.5	(19.8-143.5)	Female	22	24.2	91.0	(57.0-137.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	7	9.5	73.4	(29.4-151.3)	Male	369	359.9	102.5	(92.3-113.6)
Female	2	3.4	nc	(nc-nc)	Female	335	372.3	90.0	(80.6-100.2)
<u>Lung and Bronchus</u>									
Male	58	52.1	111.3	(84.5-143.9)					
Female	61	56.1	108.7	(83.1-139.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Boxborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	4.7	nc	(nc-nc)	Male	3	3.3	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	Female	4	2.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.0	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.2	nc	(nc-nc)	Male	4	3.0	nc	(nc-nc)
Female	22	20.4	107.6	(67.4-163.0)	Female	2	2.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.7	nc	(nc-nc)	Male	4	2.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.0	nc	(nc-nc)
Male	5	5.7	87.8	(28.3-204.9)	<u>Ovary</u>				
Female	6	4.3	138.1	(50.4-300.5)	Female	0	1.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.4	nc	(nc-nc)	Male	3	1.8	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	3	1.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.4	nc	(nc-nc)	Male	15	18.2	82.2	(46.0-135.6)
Female	1	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.2	nc	(nc-nc)
Male	2	3.2	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
Female	0	1.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	0.7	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	3	1.5	nc	(nc-nc)
<u>Leukemia</u>					Female	4	4.2	nc	(nc-nc)
Male	2	2.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	1.2	nc	(nc-nc)	Female	4	4.6	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	2.0	nc	(nc-nc)	Male	61	69.0	88.4	(67.6-113.5)
Female	0	0.5	nc	(nc-nc)	Female	68	62.5	108.8	(84.5-137.9)
<u>Lung and Bronchus</u>									
Male	7	8.7	80.5	(32.3-165.9)					
Female	9	7.8	116.0	(52.9-220.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Boxford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	9.4	63.6	(23.2-138.4)	Male	13	6.3	206.6	(109.9-353.3)
Female	1	3.0	nc	(nc-nc)	Female	9	4.3	206.9	(94.4-392.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.9	nc	(nc-nc)	Male	1	2.0	nc	(nc-nc)
Female	3	1.4	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	5	5.6	89.3	(28.8-208.5)
Female	43	37.0	116.3	(84.1-156.6)	Female	3	4.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.2	nc	(nc-nc)	Male	2	5.0	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	3	1.9	nc	(nc-nc)
Male	2	10.5	nc	(nc-nc)	<u>Ovary</u>				
Female	7	8.8	79.3	(31.8-163.3)	Female	2	3.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	2.6	nc	(nc-nc)	Male	3	3.5	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	4	3.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.6	nc	(nc-nc)	Male	43	33.3	129.0	(93.3-173.8)
Female	2	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	2.4	nc	(nc-nc)
Male	3	5.7	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
Female	2	2.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.1	nc	(nc-nc)
Male	2	1.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	2	2.5	nc	(nc-nc)
<u>Leukemia</u>					Female	9	6.6	137.3	(62.6-260.6)
Male	5	3.8	130.0	(41.9-303.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	2.5	nc	(nc-nc)	Female	6	8.5	70.6	(25.8-153.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	3.7	nc	(nc-nc)	Male	109	129.3	84.3	(69.2-101.7)
Female	0	1.1	nc	(nc-nc)	Female	119	119.6	99.5	(82.4-119.1)
<u>Lung and Bronchus</u>									
Male	9	17.6	51.1	(23.3-96.9)					
Female	10	16.6	60.3	(28.9-110.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Boylston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	5.4	110.7	(40.4-240.9)	Male	3	3.4	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)	Female	8	2.3	353.6	(152.3-696.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.0	nc	(nc-nc)	Male	4	1.1	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	3.1	nc	(nc-nc)
Female	27	18.5	146.0	(96.2-212.5)	Female	0	2.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.7	nc	(nc-nc)	Male	3	2.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.0	nc	(nc-nc)
Male	3	6.0	nc	(nc-nc)	<u>Ovary</u>				
Female	6	4.8	125.9	(46.0-274.1)	Female	2	1.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.4	nc	(nc-nc)	Male	3	1.9	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	2	1.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.4	nc	(nc-nc)	Male	15	16.6	90.5	(50.6-149.2)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	1.3	nc	(nc-nc)
Male	2	3.0	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	0.6	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
<u>Leukemia</u>					Female	4	3.5	nc	(nc-nc)
Male	1	2.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.3	nc	(nc-nc)	Female	3	4.1	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.9	nc	(nc-nc)	Male	55	69.5	79.1	(59.6-103.0)
Female	0	0.5	nc	(nc-nc)	Female	68	60.7	112.0	(87.0-142.0)
<u>Lung and Bronchus</u>									
Male	2	9.5	nc	(nc-nc)					
Female	5	8.1	62.0	(20.0-144.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Braintree

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	46	39.7	115.9	(84.9-154.6)	Male	28	24.9	112.4	(74.7-162.4)
Female	22	16.3	134.8	(84.4-204.1)	Female	22	21.1	104.4	(65.4-158.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	7.5	nc	(nc-nc)	Male	6	7.9	75.7	(27.6-164.8)
Female	6	6.7	89.4	(32.6-194.5)	Female	3	7.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.3	nc	(nc-nc)	Male	23	22.4	102.8	(65.2-154.3)
Female	195	165.9	117.5	(101.6-135.2)	Female	19	22.1	86.0	(51.8-134.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	7	5.5	128.2	(51.3-264.1)	Male	21	18.1	115.8	(71.7-177.0)
<u>Colon / Rectum</u>					Female	11	9.1	120.2	(59.9-215.1)
Male	52	42.5	122.2	(91.3-160.3)	<u>Ovary</u>				
Female	60	47.8	125.4	(95.7-161.5)	Female	16	14.5	110.4	(63.0-179.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	13	9.9	131.4	(69.9-224.7)	Male	15	14.0	107.4	(60.0-177.1)
Female	3	3.1	nc	(nc-nc)	Female	19	16.8	113.1	(68.0-176.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	5	2.9	170.0	(54.8-396.8)	Male	131	116.3	112.6	(94.2-133.7)
Female	5	2.5	200.6	(64.6-468.1)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	8	9.5	84.3	(36.3-166.2)
Male	22	21.3	103.4	(64.8-156.5)	Female	6	6.6	91.5	(33.4-199.2)
Female	13	13.5	96.6	(51.4-165.2)	<u>Testis</u>				
<u>Larynx</u>					Male	6	5.2	114.6	(41.9-249.5)
Male	3	5.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	6	1.9	319.5	(116.7-695.5)	Male	8	9.7	82.7	(35.6-163.0)
<u>Leukemia</u>					Female	38	29.7	128.0	(90.6-175.7)
Male	13	16.1	80.6	(42.9-137.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	19	13.0	146.0	(87.9-228.0)	Female	42	36.2	116.1	(83.7-157.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	13	13.4	97.2	(51.7-166.3)	Male	517	499.2	103.6	(94.8-112.9)
Female	5	5.1	97.5	(31.4-227.6)	Female	655	576.4	113.6	(105.1-122.7)
<u>Lung and Bronchus</u>									
Male	58	69.0	84.0	(63.8-108.6)					
Female	89	82.3	108.2	(86.9-133.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Brewster

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	18	18.5	97.4	(57.7-153.9)	Male	17	10.7	159.2	(92.7-255.0)
Female	6	7.0	86.2	(31.5-187.7)	Female	10	7.8	128.3	(61.4-235.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.8	nc	(nc-nc)	Male	2	3.6	nc	(nc-nc)
Female	1	2.5	nc	(nc-nc)	Female	1	3.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.6	nc	(nc-nc)	Male	13	9.5	137.4	(73.1-234.9)
Female	93	66.5	139.8	(112.9-171.3)	Female	16	9.0	177.5	(101.4-288.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.7	nc	(nc-nc)	Male	6	7.5	80.3	(29.3-174.7)
<u>Colon / Rectum</u>					Female	3	3.7	nc	(nc-nc)
Male	12	18.1	66.4	(34.3-116.0)	<u>Ovary</u>				
Female	18	18.9	95.5	(56.5-150.9)	Female	6	5.8	102.7	(37.5-223.6)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	4.5	nc	(nc-nc)	Male	5	6.3	80.0	(25.8-186.6)
Female	1	1.4	nc	(nc-nc)	Female	3	7.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.8	nc	(nc-nc)	Male	61	54.4	112.2	(85.8-144.1)
Female	0	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	4.2	nc	(nc-nc)
Male	4	9.0	nc	(nc-nc)	Female	1	2.6	nc	(nc-nc)
Female	6	5.6	107.8	(39.4-234.6)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.1	nc	(nc-nc)
Male	2	2.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.8	nc	(nc-nc)	Male	0	3.3	nc	(nc-nc)
<u>Leukemia</u>					Female	7	9.0	77.7	(31.1-160.0)
Male	9	6.6	135.7	(61.9-257.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	7	5.0	140.4	(56.3-289.3)	Female	13	15.7	82.8	(44.0-141.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	6	5.8	103.2	(37.7-224.6)	Male	211	220.9	95.5	(83.1-109.3)
Female	0	2.2	nc	(nc-nc)	Female	237	232.0	102.1	(89.5-116.0)
<u>Lung and Bronchus</u>									
Male	33	33.3	99.2	(68.3-139.4)					
Female	25	36.5	68.4	(44.3-101.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Bridgewater

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	25	26.3	95.2	(61.6-140.5)	Male	13	17.2	75.5	(40.2-129.1)
Female	13	7.6	172.0	(91.5-294.2)	Female	19	11.6	164.1	(98.8-256.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	5.6	126.1	(50.5-259.8)	Male	3	5.5	nc	(nc-nc)
Female	7	3.8	184.9	(74.1-381.0)	Female	2	3.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.9	nc	(nc-nc)	Male	8	15.8	50.7	(21.8-100.0)
Female	79	90.7	87.1	(69.0-108.5)	Female	12	11.1	107.7	(55.6-188.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	3.1	nc	(nc-nc)	Male	14	13.2	105.8	(57.8-177.6)
<u>Colon / Rectum</u>					Female	5	4.7	105.3	(33.9-245.7)
Male	29	29.6	97.9	(65.5-140.6)	<u>Ovary</u>				
Female	17	22.4	75.8	(44.1-121.4)	Female	9	7.9	114.3	(52.2-217.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	6.9	nc	(nc-nc)	Male	10	9.5	105.0	(50.3-193.0)
Female	0	1.5	nc	(nc-nc)	Female	8	7.7	103.8	(44.7-204.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	2.5	nc	(nc-nc)	Male	79	84.1	94.0	(74.4-117.1)
Female	0	1.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	6.4	77.8	(25.1-181.6)
Male	10	15.4	64.9	(31.1-119.4)	Female	3	3.1	nc	(nc-nc)
Female	8	7.0	113.9	(49.0-224.4)	<u>Testis</u>				
<u>Larynx</u>					Male	0	4.6	nc	(nc-nc)
Male	3	4.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	1.0	nc	(nc-nc)	Male	11	7.4	148.3	(73.9-265.3)
<u>Leukemia</u>					Female	30	18.5	162.4	(109.5-231.8)
Male	6	11.2	53.4	(19.5-116.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	6.5	nc	(nc-nc)	Female	19	20.6	92.4	(55.6-144.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	15	9.4	160.3	(89.6-264.4)	Male	318	349.7	90.9	(81.2-101.5)
Female	3	2.6	nc	(nc-nc)	Female	295	300.4	98.2	(87.3-110.1)
<u>Lung and Bronchus</u>									
Male	45	45.9	98.0	(71.5-131.2)					
Female	33	40.1	82.3	(56.6-115.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Brimfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	3.7	nc	(nc-nc)	Male	0	2.7	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)	Female	1	2.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.8	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	4	2.3	nc	(nc-nc)
Female	18	17.7	101.7	(60.3-160.8)	Female	4	2.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.6	nc	(nc-nc)	Male	0	2.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.9	nc	(nc-nc)
Male	3	4.4	nc	(nc-nc)	<u>Ovary</u>				
Female	1	4.1	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	1.1	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	1.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	0.3	nc	(nc-nc)	Male	9	14.8	60.6	(27.7-115.1)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	1.0	nc	(nc-nc)
Male	7	2.5	281.1	(112.6-579.2)	Female	1	0.5	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	0.5	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
<u>Leukemia</u>					Female	2	3.2	nc	(nc-nc)
Male	3	1.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.1	nc	(nc-nc)	Female	2	4.0	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.6	nc	(nc-nc)	Male	51	55.0	92.7	(69.1-121.9)
Female	0	0.5	nc	(nc-nc)	Female	38	56.0	67.8	(48.0-93.1)
<u>Lung and Bronchus</u>									
Male	7	7.2	97.0	(38.9-199.9)					
Female	4	7.7	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Brockton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	80	83.9	95.3	(75.6-118.7)	Male	24	54.8	43.8	(28.0-65.2)
Female	36	31.8	113.2	(79.3-156.8)	Female	30	46.4	64.7	(43.7-92.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	17	17.9	94.8	(55.2-151.7)	Male	11	17.5	62.9	(31.4-112.6)
Female	20	15.3	130.4	(79.6-201.4)	Female	18	14.6	123.5	(73.2-195.2)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	2.9	nc	(nc-nc)	Male	48	49.5	96.9	(71.4-128.5)
Female	317	366.7	86.5	(77.2-96.5)	Female	38	45.5	83.5	(59.1-114.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	25	13.0	191.8	(124.1-283.2)	Male	38	41.7	91.2	(64.5-125.1)
<u>Colon / Rectum</u>					Female	23	19.2	119.7	(75.9-179.6)
Male	113	92.8	121.7	(100.3-146.4)	<u>Ovary</u>				
Female	96	94.3	101.8	(82.5-124.4)	Female	44	31.5	139.6	(101.4-187.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	21	22.1	95.2	(58.9-145.6)	Male	35	30.4	115.2	(80.2-160.2)
Female	6	6.3	95.8	(35.0-208.5)	Female	47	32.3	145.5	(106.9-193.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	6	7.3	82.1	(30.0-178.8)	Male	260	271.1	95.9	(84.6-108.3)
Female	7	6.3	110.5	(44.3-227.6)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	31	20.5	151.0	(102.6-214.3)
Male	60	48.7	123.2	(94.0-158.6)	Female	12	12.8	94.1	(48.6-164.3)
Female	23	29.1	79.1	(50.1-118.7)	<u>Testis</u>				
<u>Larynx</u>					Male	12	13.3	90.0	(46.5-157.3)
Male	18	12.9	139.9	(82.9-221.1)	<u>Thyroid</u>				
Female	4	4.0	nc	(nc-nc)	Male	26	22.9	113.6	(74.2-166.4)
<u>Leukemia</u>					Female	86	73.0	117.8	(94.2-145.5)
Male	30	36.0	83.3	(56.2-118.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	17	27.3	62.4	(36.3-99.8)	Female	79	80.7	97.9	(77.5-122.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	46	30.5	151.1	(110.6-201.5)	Male	1161	1116.0	104.0	(98.1-110.2)
Female	13	10.5	123.6	(65.8-211.4)	Female	1251	1227.0	102.0	(96.4-107.8)
<u>Lung and Bronchus</u>									
Male	177	149.3	118.5	(101.7-137.3)					
Female	195	168.4	115.8	(100.1-133.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Brookfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	4.3	116.9	(37.7-272.8)	Male	1	2.8	nc	(nc-nc)
Female	2	1.4	nc	(nc-nc)	Female	2	1.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.8	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	2.5	nc	(nc-nc)
Female	14	15.3	91.6	(50.0-153.7)	Female	5	2.0	252.6	(81.4-589.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.5	nc	(nc-nc)	Male	0	2.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	3	0.8	nc	(nc-nc)
Male	4	4.5	nc	(nc-nc)	<u>Ovary</u>				
Female	5	4.1	123.2	(39.7-287.5)	Female	1	1.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	1.2	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.3	nc	(nc-nc)	Male	11	14.7	75.1	(37.4-134.3)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.0	nc	(nc-nc)
Male	2	2.5	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.5	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	4	1.1	nc	(nc-nc)
<u>Leukemia</u>					Female	4	2.7	nc	(nc-nc)
Male	1	1.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	1.1	nc	(nc-nc)	Female	4	3.5	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	1.6	nc	(nc-nc)	Male	46	57.0	80.7	(59.0-107.6)
Female	2	0.5	nc	(nc-nc)	Female	63	52.0	121.2	(93.2-155.1)
<u>Lung and Bronchus</u>									
Male	8	7.9	101.5	(43.7-199.9)					
Female	13	7.6	171.9	(91.5-294.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Brookline

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	50	53.0	94.4	(70.0-124.4)	Male	49	34.0	144.3	(106.8-190.8)
Female	18	23.2	77.7	(46.0-122.8)	Female	37	32.9	112.5	(79.2-155.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	9	10.7	84.5	(38.5-160.3)	Male	12	10.8	110.9	(57.2-193.8)
Female	14	10.5	133.0	(72.7-223.2)	Female	8	10.5	76.4	(32.9-150.5)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.8	nc	(nc-nc)	Male	35	30.5	114.6	(79.8-159.4)
Female	228	247.9	92.0	(80.4-104.7)	Female	38	32.5	117.0	(82.8-160.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	8.8	nc	(nc-nc)	Male	28	24.9	112.6	(74.8-162.8)
<u>Colon / Rectum</u>					Female	7	13.5	51.7	(20.7-106.6)
Male	33	56.2	58.8	(40.4-82.5)	<u>Ovary</u>				
Female	41	67.0	61.2	(43.9-83.1)	Female	32	21.9	146.3	(100.1-206.6)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	13.7	36.4	(11.7-85.1)	Male	23	18.9	122.0	(77.3-183.0)
Female	2	4.6	nc	(nc-nc)	Female	27	23.8	113.4	(74.7-165.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	7	4.7	150.1	(60.1-309.2)	Male	159	170.4	93.3	(79.4-109.0)
Female	5	5.0	99.6	(32.1-232.4)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	11	12.7	86.3	(43.0-154.4)
Male	36	29.6	121.4	(85.0-168.1)	Female	6	9.1	65.8	(24.0-143.3)
Female	15	20.1	74.8	(41.8-123.3)	<u>Testis</u>				
<u>Larynx</u>					Male	11	8.9	123.3	(61.5-220.6)
Male	3	8.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	2	2.8	nc	(nc-nc)	Male	14	13.9	101.1	(55.2-169.6)
<u>Leukemia</u>					Female	50	50.5	99.1	(73.6-130.7)
Male	30	21.7	138.1	(93.1-197.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	29	19.4	149.9	(100.3-215.2)	Female	45	55.8	80.6	(58.8-107.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	10	18.2	54.8	(26.2-100.8)	Male	629	692.6	90.8	(83.9-98.2)
Female	5	7.5	66.8	(21.5-155.8)	Female	759	857.8	88.5	(82.3-95.0)
<u>Lung and Bronchus</u>									
Male	57	95.2	59.9	(45.3-77.6)					
Female	77	120.4	64.0	(50.5-80.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Buckland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	2.3	nc	(nc-nc)	Male	2	1.5	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	Female	3	1.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	0.4	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
Female	7	11.3	61.8	(24.8-127.4)	Female	0	1.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.3	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.6	nc	(nc-nc)
Male	2	2.5	nc	(nc-nc)	<u>Ovary</u>				
Female	4	2.9	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.6	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	7	7.8	90.1	(36.1-185.7)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.6	nc	(nc-nc)
Male	2	1.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.3	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Leukemia</u>					Female	1	1.8	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.8	nc	(nc-nc)	Female	0	2.7	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	0.8	nc	(nc-nc)	Male	25	30.5	82.1	(53.1-121.2)
Female	0	0.4	nc	(nc-nc)	Female	31	37.9	81.7	(55.5-116.0)
<u>Lung and Bronchus</u>									
Male	1	4.1	nc	(nc-nc)					
Female	8	5.7	140.9	(60.7-277.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Burlington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	20	31.5	63.4	(38.7-98.0)	Male	18	19.2	93.5	(55.4-147.8)
Female	6	10.6	56.4	(20.6-122.8)	Female	13	14.1	91.9	(48.9-157.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	8	5.6	142.3	(61.3-280.5)	Male	7	6.1	114.0	(45.7-235.0)
Female	5	4.5	110.4	(35.6-257.6)	Female	4	4.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.0	nc	(nc-nc)	Male	23	17.2	134.1	(85.0-201.2)
Female	132	116.4	113.4	(94.9-134.5)	Female	14	14.6	96.0	(52.5-161.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	3.8	nc	(nc-nc)	Male	10	13.3	75.0	(35.9-138.0)
<u>Colon / Rectum</u>					Female	5	6.1	81.8	(26.4-190.8)
Male	26	32.7	79.6	(52.0-116.6)	<u>Ovary</u>				
Female	26	30.5	85.4	(55.7-125.1)	Female	8	9.9	80.8	(34.8-159.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	7.6	nc	(nc-nc)	Male	18	10.8	166.8	(98.8-263.6)
Female	0	2.1	nc	(nc-nc)	Female	7	10.7	65.3	(26.2-134.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	2.2	nc	(nc-nc)	Male	89	85.5	104.0	(83.6-128.0)
Female	2	1.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	7.4	nc	(nc-nc)
Male	17	15.9	106.7	(62.1-170.9)	Female	3	4.1	nc	(nc-nc)
Female	5	9.3	53.7	(17.3-125.2)	<u>Testis</u>				
<u>Larynx</u>					Male	3	3.9	nc	(nc-nc)
Male	2	4.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	1.3	nc	(nc-nc)	Male	10	7.1	141.0	(67.5-259.4)
<u>Leukemia</u>					Female	28	20.9	134.0	(89.0-193.6)
Male	16	12.3	129.6	(74.0-210.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	8.4	59.7	(19.2-139.3)	Female	32	25.5	125.4	(85.8-177.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	10	9.9	100.8	(48.3-185.4)	Male	366	381.0	96.1	(86.5-106.4)
Female	3	3.4	nc	(nc-nc)	Female	383	391.3	97.9	(88.3-108.2)
<u>Lung and Bronchus</u>									
Male	41	54.8	74.8	(53.7-101.5)					
Female	55	57.2	96.2	(72.5-125.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Cambridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	47	74.3	63.3	(46.5-84.1)	Male	51	50.5	101.0	(75.2-132.8)
Female	13	29.9	43.5	(23.1-74.3)	Female	46	48.0	95.9	(70.2-127.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	25	17.9	139.6	(90.3-206.1)	Male	17	15.2	111.8	(65.1-179.0)
Female	14	15.1	92.5	(50.5-155.2)	Female	10	13.7	72.9	(34.9-134.0)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	4	2.6	nc	(nc-nc)	Male	42	45.7	91.8	(66.2-124.1)
Female	318	339.2	93.7	(83.7-104.6)	Female	45	43.8	102.6	(74.9-137.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	7	13.6	51.6	(20.7-106.3)	Male	42	35.9	117.0	(84.3-158.2)
<u>Colon / Rectum</u>					Female	16	18.2	87.9	(50.2-142.7)
Male	67	81.0	82.7	(64.1-105.1)	<u>Ovary</u>				
Female	67	87.1	76.9	(59.6-97.7)	Female	29	30.2	96.0	(64.3-137.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	16	19.1	83.8	(47.9-136.1)	Male	32	26.4	121.1	(82.8-171.0)
Female	5	6.0	83.8	(27.0-195.6)	Female	25	30.4	82.4	(53.3-121.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	8	10.7	74.8	(32.2-147.4)	Male	253	231.9	109.1	(96.1-123.4)
Female	4	9.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	12	18.1	66.3	(34.2-115.8)
Male	31	43.0	72.1	(49.0-102.4)	Female	8	11.9	67.0	(28.9-132.0)
Female	17	27.1	62.7	(36.5-100.4)	<u>Testis</u>				
<u>Larynx</u>					Male	19	22.5	84.4	(50.8-131.8)
Male	4	11.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	3.7	nc	(nc-nc)	Male	27	23.6	114.4	(75.3-166.4)
<u>Leukemia</u>					Female	85	81.0	104.9	(83.8-129.7)
Male	28	33.2	84.3	(56.0-121.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	16	26.4	60.5	(34.6-98.3)	Female	65	75.8	85.8	(66.2-109.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	16	25.5	62.8	(35.9-102.0)	Male	914	1001.6	91.3	(85.4-97.4)
Female	10	10.0	100.0	(47.9-184.0)	Female	981	1170.7	83.8	(78.6-89.2)
<u>Lung and Bronchus</u>									
Male	109	131.9	82.6	(67.9-99.7)					
Female	107	157.5	67.9	(55.7-82.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Canton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	23	26.4	87.2	(55.2-130.8)	Male	20	16.4	122.2	(74.6-188.8)
Female	7	9.8	71.2	(28.5-146.7)	Female	14	12.8	109.0	(59.5-182.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	4.8	103.7	(33.4-242.1)	Male	10	5.3	189.0	(90.5-347.5)
Female	6	4.1	145.0	(52.9-315.5)	Female	5	4.4	113.7	(36.7-265.4)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.9	nc	(nc-nc)	Male	12	14.7	81.7	(42.2-142.7)
Female	106	104.3	101.6	(83.2-122.9)	Female	17	13.4	126.9	(73.9-203.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	3.4	nc	(nc-nc)	Male	11	11.8	93.5	(46.6-167.3)
<u>Colon / Rectum</u>					Female	8	5.6	143.4	(61.8-282.7)
Male	35	27.7	126.5	(88.1-175.9)	<u>Ovary</u>				
Female	30	28.3	105.9	(71.4-151.2)	Female	6	8.9	67.1	(24.5-146.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	9	6.6	136.7	(62.4-259.5)	Male	8	9.3	86.1	(37.1-169.6)
Female	1	1.9	nc	(nc-nc)	Female	9	10.0	89.6	(40.9-170.1)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.8	nc	(nc-nc)	Male	85	78.3	108.5	(86.7-134.2)
Female	1	1.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	6	6.3	95.6	(34.9-208.0)
Male	9	14.0	64.1	(29.3-121.8)	Female	3	3.8	nc	(nc-nc)
Female	5	8.4	59.4	(19.1-138.5)	<u>Testis</u>				
<u>Larynx</u>					Male	3	3.0	nc	(nc-nc)
Male	2	3.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	2	1.2	nc	(nc-nc)	Male	11	6.1	179.0	(89.2-320.3)
<u>Leukemia</u>					Female	35	18.4	190.1	(132.4-264.3)
Male	18	10.4	172.4	(102.1-272.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	7.8	64.2	(20.7-149.8)	Female	27	22.9	118.0	(77.8-171.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	8.7	nc	(nc-nc)	Male	357	330.0	108.2	(97.2-120.0)
Female	0	3.1	nc	(nc-nc)	Female	373	355.1	105.0	(94.6-116.3)
<u>Lung and Bronchus</u>									
Male	51	46.6	109.3	(81.4-143.8)					
Female	52	51.5	100.9	(75.4-132.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;